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OBJECTIVES The objective of this investigation was to define for the first time the cardiorenal and humoral
actions of repeated short-term administration of subcutaneous (SQ) brain natriuretic peptide
(BNP) administration during the evolution of experimental heart failure.
BACKGROUND The rationale of this study was based on BNP as a vasodilating, natriuretic, renin-inhibiting
and lusitropic peptide of cardiac origin.
METHODS First, we defined the cardiorenal and humoral responses to acute low and high dose (5 mg/kg
or 25 mg/kg) of SQ BNP in experimental heart failure to establish the acute efficacy of an SQ
delivery. Second, we characterized the response to 10 days of repeated short-term adminis-
tration of BNP during the evolution of experimental heart failure produced by rapid
ventricular pacing.
RESULTS Plasma BNP and 39,59-cyclic guanosine monophosphate rapidly increased and peaked at
30 min after acute SQ BNP administration with increases in urinary sodium excretion, urine
flow and renal blood flow in association with reductions in cardiac filling pressures. After 10
days of repeated short-term administration of SQ BNP, cardiac output was increased and
systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as
compared with untreated dogs with heart failure.
CONCLUSIONS This study demonstrated for the first time that repeated short-term administration of SQ
BNP administration for 10 days during the evolution of left ventricular dysfunction in a
canine model results in an improvement in cardiovascular hemodynamics. This investigation
supports a potential novel strategy for the chronic administration of BNP in the therapeutics
of heart failure. (J Am Coll Cardiol 2000;36:1706–12) © 2000 by the American College of
Cardiology
Brain natriuretic peptide (BNP) is a 32-amino acid peptide
with natriuretic, renin-inhibiting (1), vasodilating and lusi-
tropic properties (2). Originally isolated from porcine brain,
BNP was subsequently found to be synthesized and secreted
in greatest abundance in cardiomyocytes (3–5). Brain natri-
uretic peptide is structurally similar to atrial natriuretic
peptide (ANP) but genetically distinct. Both are of myo-
cardial cell origin and play a role in the control of sodium
excretion and arterial blood pressure. Specifically, studies
have established that BNP, like ANP, binds to the natri-
uretic peptide receptor which, via 39,59-cyclic guanosine
monophosphate (cGMP), mediates its biological actions
(6,7). Despite these similarities, BNP has emerged as the
more biologically potent peptide based upon its greater
natriuretic actions, its decreased susceptibility for degrada-
tion by neutral endopeptidase 24.11 and its enhanced ability
to augment cGMP (8,9). Circulating BNP is also superior
to ANP as a diagnostic serum marker for altered ventricular
structure and function and for identification of patients with
asymptomatic left ventricular dysfunction (10,11).
Recognizing the greater cardiorenal potency of BNP
compared with ANP, intravenous BNP infusion in humans
with congestive heart failure (CHF) has recently been
pursued as a therapeutic approach to acutely decompensated
heart failure. These investigations have demonstrated that
acute intravenous BNP decreases pulmonary artery pressure
(PAP), pulmonary capillary wedge pressure (PCWP), right
atrial pressure (RAP) and mean arterial pressure (MAP) and
increases cardiac index, urine volume and urine sodium
excretion (UNaV) without associated neurohumoral activa-
tion (12–14). Acute BNP infusion in normal humans
reduces isovolumic relaxation time of the left ventricle and
improves transmitral Doppler flow profiles, suggesting that
this peptide may enhance left ventricular diastolic relaxation
(15). Indeed, such lusitropic properties were recently re-
ported in experimental studies in dogs with and without
heart failure (2). While such beneficial cardiorenal and
endocrine actions of acute intravenous BNP administration
in CHF are now well established, the effects of chronic BNP
administration in CHF remain undefined, as does a strategy
for more long-term BNP administration.
This study was designed to define the cardiorenal and
endocrine actions of repeated short-term administration of
BNP administered subcutaneously (SQ) for 10 days during
the evolution of experimental heart failure in a canine
model. First, we defined the cardiorenal and humoral
responses to acute low- and high-dose SQ BNP in experi-
mental heart failure to establish the efficacy of this delivery
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route. Second, we defined the cardiorenal and humoral
responses to repeated short-term administration of SQ
BNP for 10 days during the evolution of experimental heart
failure based on the findings of the acute studies. We
hypothesized that repeated short-term administration of SQ
BNP during the evolution of experimental heart failure
would result in improved cardiovascular hemodynamics
when compared with untreated heart failure.
METHODS
Studies were conducted in three groups of anesthetized male
mongrel dogs (18 to 23 kg) with chronic heart failure
produced by rapid ventricular pacing at 180 beats/min for 10
days on a fixed sodium diet (16). The three groups consisted
of an acute low dose BNP group (n 5 5), an acute high dose
BNP group (n 5 7) and a chronic BNP group (n 5 6).
Studies were performed in accordance with the Animal
Welfare Act and with approval of the Mayo Clinic Institu-
tional Animal Care and Use Committee.
Model of pacing-induced chronic heart failure. All dogs
underwent implantation of a programmable cardiac pace-
maker (Medtronic, Minneapolis, Minnesota). Under pen-
tobarbital sodium anesthesia (30 mg/kg, intravenous) and
artificial ventilation (Harvard respirator, Harvard Appara-
tus, Millis, Massachusetts) with 5 L/min supplemental
oxygen, a left lateral thoracotomy and pericardiotomy were
performed. With the heart exposed, a screw-in epicardial
pacemaker lead was implanted into the right ventricle. The
pacemaker generator was implanted SQ into the left chest
wall and connected to the pacemaker lead. Dogs received
pre- and postoperative prophylactic antibiotic treatment
with 225 mg clindamycin SQ and 400,000 U procaine
penicillin G plus 500 mg dihydrostreptomycin intramuscu-
larly (Combiotic, Pfizer, Inc., New York, New York).
Postoperative prophylactic antibiotic was continued through
the first 2 postoperative days. Dogs were fed a fixed sodium
diet (58 mEq/day, Hill’s ID) and allowed water ad lib. All
dogs were walked daily. Appetite, activity, body temperature
and condition of surgical skin sites were documented. After
a 14 day postoperative recovery period, the pacemaker was
turned on at 180 beats/min.
Acute low- and high-dose SQ BNP. On day 11 of rapid
ventricular pacing at 180 beats/min, acute low dose SQ
BNP (5 mg/kg, n 5 5) or acute high-dose SQ BNP
(25 mg/kg, n 5 7) was administered to two separate groups
of dogs with heart failure. On the night before the acute
experiment, animals were fasted and given 300 mg of
lithium carbonate for assessment of renal tubular function.
On the day of the acute experiment, dogs were anesthetized
with sodium pentobarbital (15 mg/kg, intravenous), intu-
bated and mechanically ventilated with supplemental oxy-
gen (Harvard respirator, Amersham, Massachusetts) at 20
cycles per minute. A flow-directed balloon-tipped ther-
modilution catheter (Ohmeda, Criticath, Madison, Wis-
consin) was advanced into the pulmonary artery via the
external jugular vein for cardiac hemodynamic measure-
ment. The femoral artery was cannulated for blood pressure
monitoring and blood sampling. The femoral vein was also
cannulated for inulin and normal saline infusion. The left
kidney was exposed via a flank incision, and the ureter was
cannulated for urine collection. A calibrated electromag-
netic flow probe was placed around the renal artery to
measure renal blood flow (RBF).
The experiment began after a 60 min equilibration
period, with a 30 min baseline urinary clearance. After the
30 min baseline urinary clearance, canine BNP 5 mg/kg
(acute low-dose group) or 25 mg/kg (acute high-dose group)
dissolved in 1 ml of normal saline was given SQ in the left
hind limb. After a 15 min lead-in period, two 30 min
clearance periods were carried out followed by four 60 min
clearances for a total duration of 5 h after administration of
SQ BNP. Cardiovascular parameters measured during the
acute experiment included MAP, RAP, PAP, cardiac out-
put (CO) and PCWP. Cardiac output was determined by
thermodilution in triplicate and averaged (Cardiac Output
model 9510-A computer, American Edwards Laboratories,
Irvine, California). Mean arterial pressure was assessed via
direct measurement from the femoral arterial catheter.
Systemic vascular resistance (SVR) was calculated as
(SVR 5 [MAP 2 RAP]/CO). Inulin was administered
intravenously at the start of the equilibration period as a
calculated bolus followed by a 1 mL/min continuous infu-
sion to achieve plasma levels of 40 to 60 mg/dl. Glomerular
filtration rate (GFR) was measured by inulin clearance.
Renal vascular resistance (RVR) was calculated as (RVR 5
[MAP 2 RAP]/RBF).
Cardiovascular hemodynamics was measured at the start
of each clearance. Arterial blood was collected in heparin
and EDTA tubes and immediately placed on ice midway
through each clearance. After centrifugation at 2,500 rpm at
4°C, plasma was decanted and stored at 220°C until
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
cGMP 5 39,59-cyclic guanosine monophosphate
CHF 5 congestive heart failure
CLLi 5 lithium clearance
CO 5 cardiac output
DFNaR 5 distal fractional reabsorption of sodium
GFR 5 glomerular filtration rate
MAP 5 mean arterial pressure
PAP 5 pulmonary artery pressure
PCWP 5 pulmonary capillary wedge pressure
PFNaR 5 proximal fractional reabsorption of sodium
RAP 5 right atrial pressure
RBF 5 renal blood flow
RIA 5 radioimmunoassay
RVR 5 renal vascular resistance
SQ 5 subcutaneous or subcutaneously
SVR 5 systematic vascular resistance
UcGMPV 5 urinary cGMP excretion
UNaV 5 urine sodium excretion
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analysis. Urine was collected on ice during the entire period
of each clearance for assessment of urine volume, electro-
lytes and inulin. Urine collected for cGMP analysis was
heated to more than 90°C before storage.
Chronic SQ BNP. In a third group of dogs, SQ BNP was
administered at a dose of 5 mg/kg every 8 h throughout the
10 days of evolving heart failure. This dose was chosen
based upon the favorable cardiorenal effects observed in the
acute studies (see Results section). On day 11, complete
cardiorenal and neurohumoral measurements were assessed
8 h after the previous dose following the same protocol used
in the acute studies described in detail above.
Hormonal and electrolyte analysis. After extraction
plasma ANP and BNP were measured by radioimmunoas-
say (RIA) as previously described (1,17). Plasma and urinary
samples for cGMP were measured by RIA using the
method of Steiner et al. (18). Plasma renin activity was
determined by RIA using the methods of Haber et al. (19).
Urinary and plasma inulin concentrations were measured by
the anthrone method. Urinary and plasma lithium levels
were determined by flame emission spectrophotometry
(model 357, Instrumentation Laboratory, Wilmington,
Massachusetts). Employing the lithium clearance (CLLi)
technique, proximal and distal fractional reabsorption of
sodium (PFNaR and DFNaR, respectively) were calculated
utilizing the following equation: PFNaR 5 (1 2 [CLLi/
GFR]) 3 100, DFNaR 5 (CLLi 2 CLNa)/CLLi 3 100,
where CLLi 5 (urine Li 3 urine flow)/plasma Li and
CLNa 5 (urine Na 3 urine flow)/plasma Na.
Statistical analysis. Results are expressed as mean 6 SEM.
Two-way repeated measures analysis of variance was used
for all comparisons between two groups and one-way
repeated measures analysis of variance for comparisons
within each group using GraphPad Prism software. Statis-
tical significance was accepted as p , 0.05.
RESULTS
Acute low- and high-dose SQ BNP. The responses of
plasma BNP and cGMP and urinary cGMP excretion
(UcGMPV) in the acute low- and high-dose SQ BNP
groups are illustrated in Figure 1. Plasma BNP and cGMP
increased in response to SQ BNP and peaked at 30 min in
both groups. Urinary cGMP excretion also increased in
response to SQ BNP but peaked at 60 min in both groups.
Plasma BNP, plasma cGMP and UcGMPV returned to
baseline by 180 min after SQ administration of BNP in
both groups. The increases in plasma BNP, plasma cGMP
and UcGMPV were significantly higher in the acute high-
dose group as compared with the acute low-dose group.
Plasma ANP remained unchanged in both groups with the
administration of SQ BNP.
The responses in RAP and PWCP to SQ BNP in both
the acute low-dose and the acute high-dose groups are
illustrated in Figure 2. Right atrial pressure, PCWP (Fig. 2)
and PAP (Table 1) were significantly reduced in both
groups after SQ BNP administration with the peak response
at 60 min after administration. In the acute low-dose group,
RAP, PWCP and PAP remained significantly reduced at
300 min, while these parameters in the acute high-dose
group returned to baseline by 180 min. In the acute
low-dose group, there were no significant changes in CO,
MAP or SVR (Table 1). In contrast, in the acute high-dose
group, BNP significantly increased CO at 30 min, which
returned to baseline by 120 min, but subsequently declined
below baseline at 240 and 300 min (Table 1). In addition, in
the acute high-dose group, BNP decreased MAP at 30 min,
which returned to baseline by 180 min in association with a
decrease in SVR at 30 min, which returned to baseline at
120 min and subsequently increased significantly above
baseline at 180 min to 300 min (Table 1). Of note, CO was
significantly lower and SVR significantly higher in the
high-dose group compared with the low-dose group at
300 min.
The responses of UNaV and DFNaR to SQ BNP in both
acute low- and high-dose groups are illustrated in Figure 2.
Urine sodium excretion (Fig. 2) and urine flow (Table 1)
peaked 30 min after SQ BNP administration and returned
to baseline by 180 min in both groups. This was accompa-
Figure 1. Plasma BNP and plasma cGMP and UcGMPV excretion BL,
30, 60, 120, 180, 240 and 300 min after SQ BNP administration. Open
bar 5 acute low-dose group; solid bar 5 acute high-dose group. *p , 0.05
vs. BL; †p , 0.05 vs. acute low-dose group. BL 5 baseline; BNP 5 brain
natriuretic peptide; cGMP 5 39,59-cyclic guanosine monophosphate;
SQ 5 subcutaneous; UcGMPV 5 urinary cGMP excretion.
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nied by a decrease in DFNaR (Fig. 2) and PFNaR (Table
1), which also returned to baseline by 180 min. The
magnitude and duration of the natriuresis and diuresis were
similar in both low- and high-dose groups. Renal blood
flow increased 60 min after SQ BNP in the low-dose group
together with a decrease in RVR, which was sustained at
300 min (Table 1). In contrast, in the high-dose group,
RBF increased and RVR decreased at 30 min but returned
to baseline by 180 min (Table 1). Of note, at 300 min RBF
was significantly higher in the low-dose group compared
with the high-dose group. There were no significant
changes in GFR in either group during the entire protocol
(Table 1). Plasma renin activity decreased with administra-
tion of SQ BNP in both groups and returned to baseline by
300 min (Table 1); however, this was not statistically
significant (p 5 0.07).
Figure 2. Right atrial pressure, PCWP, UNaV, DFNaR at BL, 30, 60, 120, 180, 240 and 300 min after SQ BNP administration. *p , 0.05 vs. BL. BL 5
baseline; DFNaR 5 distal fractional reabsorption of sodium; PCWP 5 pulmonary capillary wedge pressure; RAP 5 right atrial pressure; SQ 5
subcutaneously; UNaV 5 urine sodium excretion.
Table 1. Hemodynamic, Renal and Humoral Responses to Acute Subcutaneous BNP
Baseline 30 min 60 min 120 min 180 min 300 min
Low-dose group (5 mg/kg), n 5 5
MAP, mm Hg 115 6 9 111 6 9 110 6 9 113 6 8 118 6 9 117 6 9
CO, l/min 2.5 6 0.1 2.8 6 0.2 2.4 6 0.1 2.3 6 0.1 2.7 6 0.3 2.8 6 0.2
SVR, RU 45 6 4 39 6 2 45 6 3 50 6 6 45 6 3 42 6 2
PAP, mm Hg 21 6 2 18 6 2 17 6 1* 18 6 2* 19 6 1* 18 6 2*
GFR, ml/min 42 6 17 44 6 12 41 6 3 37 6 4 68 6 30 49 6 11
UV, ml/min 0.26 6 0.10 1.58 6 0.33* 1.22 6 0.24* 0.62 6 0.10 0.40 6 0.07 0.31 6 0.06
PFNaR, % 75 6 7 64 6 7* 67 6 7* 67 6 7* 77 6 7 80 6 5
RBF, ml/min 145 6 34 174 6 37 209 6 28* 215 6 31* 225 6 29* 236 6 37*
RVR, RU 0.92 6 0.18 0.73 6 0.14 0.55 6 0.05* 0.55 6 0.06* 0.55 6 0.06* 0.53 6 0.08*
PRA, ng/ml/h 3.2 6 2.6 0.64 6 0.46 0.78 6 0.63 1.8 6 0.83 2.5 6 1.55 4.9 6 2.33
High-dose group (25 mg/kg), n 5 7
MAP, mm Hg 116 6 3 92 6 4* 92 6 2* 101 6 2 116 6 3 116 6 4
CO, l/min 2.6 6 0.1 3.2 6 0.3* 2.6 6 0.35 2.1 6 0.3 1.8 6 0.2*† 1.7 6 0.1*†
SVR, RU 44 6 2 30 6 3* 38 6 4* 42 6 7 64 6 6*† 64 6 4.1*†
PAP, mm Hg 20 6 0.7 16 6 0.5 16 6 0.6 16 6 0.7 20 6 1.4 22 6 0.9
GFR, ml/min 57 6 33 41 6 7 44 6 6 47 6 17 34 6 6 38 6 9
UV, ml/min 0.10 6 0.02 1.8 6 0.43* 1.4 6 0.26* 0.50 6 0.14 0.30 6 0.09 0.29 6 0.07
PFNaR, % 91 6 4 64 6 6* 68 6 3* 75 6 3* 76 6 5.4 83 6 5
RBF, ml/min 134 6 15 202 6 23* 203 6 25* 178 6 25* 157 6 23 154 6 25
RVR, RU 0.86 6 0.10 0.46 6 0.04* 0.47 6 0.04* 0.59 6 0.08* 0.81 6 0.11 0.88 6 0.15
PRA, ng/ml/h 8.7 6 2.3 3.7 6 1.0 3.7 6 1.4 5.64 6 2.3 6.7 6 2.5 7.4 6 2.8
*p , 0.05 vs. baseline; †p , 0.05 vs. low-dose group. Values are expressed as mean 6 SEM.
BNP 5 brain natriuretic peptide; CO 5 cardiac output; GFR 5 glomerular filtration rate; MAP 5 mean arterial pressure; PAP 5 pulmonary artery pressure; PFNaR 5
proximal tubular fractional reabsorption of sodium; PRA 5 plasma renin activity; RBF 5 renal blood flow; RVR 5 renal vascular resistance; SVR 5 systemic vascular resistance;
UV 5 urine flow.
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Chronic SQ BNP. Figure 3 illustrates CO, PCWP and
SVR of the chronic SQ BNP group on day 11, 8 h after the
previous dose of SQ BNP, as compared with untreated dogs
with heart failure.
The parameters for the untreated group with heart failure
were derived from the baseline measurements on day 11 of
rapid ventricular pacing of the dogs used in the acute studies
(n 5 12). Chronic SQ BNP administration for 10 days
resulted in a higher CO and lower PCWP and SVR as
compared with untreated heart failure. There was a trend for
RAP to be lower with chronic SQ BNP as compared with
untreated heart failure (1.5 6 0.4 vs. 1.8 6 0.3 mm Hg, p .
0.05). Plasma BNP levels (71 6 9 vs. 52 6 11 pg/ml, p .
0.05) and renin activity (8.0 6 2.0 vs. 6.5 6 1.8 ng/ml/h,
p . 0.05) were similar between the chronic SQ BNP group
as compared with the group with heart failure that was
untreated.
DISCUSSION
The objective of this investigation was to define for the first
time the cardiorenal and humoral actions of repeated
short-term SQ BNP administration for 10 days during the
evolution of pacing-induced left ventricular dysfunction.
We first demonstrated that acute low- and high-dose SQ
BNP rapidly increased plasma BNP and its second messen-
ger cGMP, resulting in significant natriuresis, renal vasodi-
latation with decreases in cardiac filling pressures without
activation of plasma renin activity. We also observed that
the decrease in cardiac filling pressures and renal vasodila-
tation was more sustained with low-dose as compared with
high-dose SQ BNP. Most importantly, this investigation
established that repeated short-term SQ BNP administra-
tion for 10 days during the evolution of pacing-induced left
ventricular dysfunction improved CO and decreased PCWP
and SVR in the absence of activation of plasma renin
activity when compared with an untreated group with heart
failure. This investigation supports the conclusion that
repeated short-term SQ BNP administration during the
evolution of pacing-induced left ventricular dysfunction has
favorable hemodynamic effects.
Acute low- and high-dose SQ BNP administration.
Within 30 min of SQ administration of either low- or
high-dose SQ BNP, plasma BNP significantly increased.
Thus, BNP was rapidly absorbed and resulted in activation
of natriuretic peptide receptors, as demonstrated by parallel
increases in both plasma and urinary cGMP, markers of
tissue and renal biological activity of the natriuretic peptides
(20). The increases in plasma BNP and cGMP persisted for
2 h, which is longer than the changes reported with bolus
intravenous injection (21). If the duration of receptor
stimulation is of importance for the biological actions of
BNP, then the SQ route may be more functionally signif-
icant as compared with acute intravenous bolus injection in
heart failure.
Low-dose acute SQ BNP resulted in sustained reductions
in RAP and PCWP and a maintenance of CO, MAP and
SVR. This is in contrast with high-dose SQ BNP, which
resulted in an initial decrease in cardiac filling pressures,
which returned to baseline by the third hour. This short-
ened response in cardiac filling pressures to high-dose SQ
BNP was associated with an initial increase in CO and
decrease in MAP and SVR. Cardiac output and SVR
subsequently decreased and increased, respectively, when
compared with baseline at the fourth hour. In contrast with
the acute low-dose, high-dose BNP transiently decreased
MAP. We speculate that this peripheral vasodilation may
have resulted in activation of counterregulatory mechanisms
other than the renin–angiotensin system, such as the
sympathetic nervous system and endothelin, resulting in
increased SVR and decreased CO, thereby offsetting the
Figure 3. Cardiac output, PCWP and SVR of the dogs in the chronic BNP group (treated HF) on day 11 or rapid ventricular pacing compared with dogs
with untreated HF on day 11 of rapid ventricular pacing. *p , 0.05 vs. untreated HF. BNP 5 brain natriuretic peptide; CO 5 cardiac output; HF 5 heart
failure; PCWP 5 pulmonary capillary wedge pressure; SVR 5 systemic vascular resistance.
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initial reductions in cardiac filling pressures. However, the
exact mechanism of this biphasic hemodynamic response
observed after acute high-dose BNP-induced vasodilation
requires further investigation.
Subcutaneous administration of acute low- and high-dose
BNP resulted in a rapid natriuresis and diuresis that
persisted for 2 h. The natriuresis and diuresis were similar
between the two groups despite the greater increase in
plasma BNP and cGMP and UcGMPV in the high-dose
group. The decrease in arterial pressure with high-dose
BNP may account for the lack of greater natriuretic and
diuretic actions in the high-dose group because it is known
that reductions in renal perfusion pressure attenuate the
renal responsiveness to ANP (22). The mechanism of
BNP-mediated natriuresis in this study was related to a
decrease in tubular reabsorption of sodium. This occurred at
both the proximal and distal tubules, the latter a site rich in
natriuretic peptide receptors. At the proximal tubule, in-
creases in RBF may have altered peritubular capillary
hydrostatic forces favoring a decrease in proximal tubular
reabsorption of sodium. It should be noted that there was no
associated activation of plasma renin activity with BNP-
mediated natriuresis and diuresis, which supports the renin-
inhibiting actions of BNP as compared with conventional
diuretics that activate the renin–angiotensin system.
Repeated short-term SQ BNP administration. The most
important finding of this study was that repeated short-term
SQ BNP administration for 10 days during the evolution of
heart failure in this canine model resulted in a higher CO
and lower PCWP and SVR in the absence of activation of
plasma renin activity, as compared with heart failure that
was untreated. The dose used in the 10 day chronic study
was based upon the finding that acute low-dose SQ BNP
resulted in a prompt natriuresis and diuresis equal to that
observed with high-dose BNP, together with more sus-
tained reductions in cardiac filling pressures without a
decrease in MAP. We interpret the current findings as
support for the conclusion that repeated short-term SQ
BNP administered during the evolution of experimental
heart failure has important beneficial cardiovascular and
humoral actions.
This study may have important therapeutic implications.
To date, the long-term medical treatment of heart failure
has been limited to the use of orally active pharmacological
agents. Many of these agents, such as angiotensin-
converting enzyme inhibitors, beta-adrenergic blocking
agents and endothelin-receptor blockers, oppose the actions
of vasoconstricting, growth-promoting and sodium-
retaining neurohumoral systems. Attempts have recently
been made to promote activation or restoration of endoge-
nous vasodilating, natriuretic and antimitogenic systems,
which function via the second messenger, cGMP, such as
the nitric oxide system with oral L-arginine (23) and the
natriuretic peptide system with oral neutral endopeptidase
inhibitors (24). With the beneficial effects of repeated
short-term SQ BNP administration, this study supports the
conclusion that further investigations utilizing chronic SQ
BNP as a therapeutic strategy for the management of heart
failure are clearly warranted to establish the safety and
effective dose in human heart failure.
Conclusions. This study established that acute SQ admin-
istration of BNP results in rapid peptide absorption with
beneficial cardiorenal and neurohumoral responses in a
canine model of chronic heart failure. Most importantly, the
current investigation established that repeated short-term
SQ BNP administration during the evolution of heart
failure in this model improves CO and decreases PCWP
and SVR in the absence of activation of plasma renin
activity. This novel route of BNP administration provides a
potentially novel therapeutic strategy that allows for the
chronic administration of this peptide of cardiac origin in
the management of CHF.
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